Haemonetics Corporation $HAE Shares Sold by Boston Partners

Key Points

• Boston Partners reduced its stake in Haemonetics Corporation by 0.9%, owning approximately 1.06% of the company, valued at $33.41 million after selling 4,831 shares.
• Analyst ratings for Haemonetics vary, with a consensus rating of "Moderate Buy" and a price target averaging $85.18, following several upgrades and downgrades from various institutions.
• Haemonetics reported an EPS of $1.10 for the previous quarter, exceeding expectations, although its revenue decreased by 4.4% compared to last year.

Boston Partners cut its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 0.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 531,431 shares of the medical instruments supplier's stock after selling 4,831 shares during the quarter. Boston Partners owned about 1.06% of Haemonetics worth $33,412,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Citigroup Inc. lifted its position in shares of Haemonetics by 87.3% during the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier's stock worth $39,755,000 after purchasing an additional 291,574 shares during the last quarter. Voya Investment Management LLC lifted its position in shares of Haemonetics by 820.5% during the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock worth $24,748,000 after purchasing an additional 282,521 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Haemonetics by 434.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock worth $24,522,000 after purchasing an additional 255,338 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Haemonetics during the fourth quarter worth $19,002,000. Finally, Fort Washington Investment Advisors Inc. OH lifted its position in shares of Haemonetics by 88.6% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 517,086 shares of the medical instruments supplier's stock worth $32,861,000 after purchasing an additional 242,956 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Robert W. Baird started coverage on Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 target price for the company. Barrington Research cut their price target on Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Baird R W upgraded Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Mizuho cut their price target on Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $85.18.

Haemonetics Stock Up 0.3%

NYSE HAE traded up $0.1850 during trading on Wednesday, hitting $54.4850. The company's stock had a trading volume of 1,272,177 shares, compared to its average volume of 1,167,322. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. Haemonetics Corporation has a fifty-two week low of $50.68 and a fifty-two week high of $94.99. The company has a market cap of $2.62 billion, a PE ratio of 16.66, a P/E/G ratio of 1.00 and a beta of 0.40. The business's 50 day simple moving average is $70.12 and its 200-day simple moving average is $66.49.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The firm had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. During the same quarter in the previous year, the company posted $1.02 earnings per share. The company's revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.